The recent surge in investments into specialized pharmaceutical companies, particularly those focusing on novel therapies and difficult drug development programs, has fueled what some are calling "High Roller Pharma." While the promise for blockbuster treatments and substantial returns is undeniable, the linked risks are also significant. Many of t